Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.38 |
| ▸ | PGK2 | P07205 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759926 | 0.83 | PGK1 (0.38) | PGK1PGK2IDO1LMNA | |
| SCHEMBL1334895 | 0.82 | FPR2 (0.38) | PGK1PGK2ALDH1A1POLBLMNA | |
| SCHEMBL1407856 | 0.82 | TRPA1 (0.42) | POLBHPGD | |
| SCHEMBL915155 | 0.81 | FOLH1 (0.47) | — | |
| SCHEMBL9155895 | 0.81 | SRC (0.41) | PGK1PGK2MAOBALDH1A1 | |
| SCHEMBL6878860 | 0.81 | IDO1 (0.42) | MAOBALDH1A1IDO1AGXTLMNA | |
| SCHEMBL9055030 | 0.81 | PGK1 (0.33) | PGK1PGK2 | |
| SCHEMBL1680702 | 0.80 | GLA (0.59) | PGK1PGK2MAOBALDH1A1MAPT | |
| SCHEMBL17969143 | 0.80 | ACP3 (0.59) | PGK1PGK2MAOBMAPTIDO1 | |
| SCHEMBL16398832 | 0.79 | PGK1 (0.44) | PGK1PGK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053598-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1745014-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | NOVO NORDISK A/S (CZ) | 2009-01-08 | — | — | US | disclosed |
| EP-1745014-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105736-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | PPARG, PPARD, PPARA | PGK1 584/4885PGK2 424/4885MAOB 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.